To systematically identify ubiquitin pathway genes that are critical to lung carcinogenesis, we used a genome-wide silencing method in this study to knockdown 696 genes in non-small cell lung cancer (NSCLC) cells. We identified 31 candidates that were required for cell proliferation in two NSCLC lines, among which the E2 ubiquitin conjugase CDC34 represented the most significant one. CDC34 was elevated in tumor tissues in 67 of 102 (65.7%) NSCLCs, and smokers had higher CDC34 than nonsmokers. The expression of CDC34 was inversely associated with overall survival of the patients. Forced expression of CDC34 promoted, whereas knockdown of CDC34 inhibited lung cancer in vitro and in vivo. CDC34 bound EGFR and competed with E3 ligase c-Cbl to inhibit the polyubiquitination and subsequent degradation of EGFR. In EGFR-L858R and EGFR-T790M/Del(exon 19)-driven lung cancer in mice, knockdown of CDC34 by lentivirus mediated transfection of short hairpin RNA significantly inhibited tumor formation. These results demonstrate that an E2 enzyme is capable of competing with E3 ligase to inhibit ubiquitination and subsequent degradation of oncoprotein substrate, and CDC34 represents an attractive therapeutic target for NSCLCs with or without drug-resistant EGFR mutations.
Introduction
The ubiquitin (Ub)-proteasome system (UPS) is the principal pathway for diverse intracellular protein degradation, in which the E2 ubiquitin-conjugating enzymes play critical roles by transferring the Ub on their conserved cysteine residue to the ε-amino group of lysine residues on substrates 1 . The cell division cycle 34 (CDC34, or UBCH3, Ubc3, UBE2R1) is an E2
enzyme which contains a non-covalent Ub binding domain in its carboxyl terminus 2 and employs distinct sites to coordinate attachment of Ub to a substrate and assembly of polyubiquitin chains 3 . CDC34 functions in conjunction with the Skp1-Cullin 1-F-box (SCF) E3
Ub ligase to catalyze covalent attachment of polyubiquitin chains to substrates such as p27 4 , ATF5 5 , WEE1 6 , IκBα 7 , Grr1 8 , c-Ski 9 , Sic1 10 , Far1 11 , and other substrate proteins. However, whether CDC34 and other E2s have biological functions besides E2 activity remains to be investigated.
Hyperactivation of the epidermal growth factor receptor (EGFR) by gain-of-function mutations and overexpression have been found in more than a half of patients with non-small cell lung cancers (NSCLCs) 12, 13 , and inhibition of constitutively activated EGFR significantly benefits lung adenocarcinoma patients with mutant EGFR 14 . The proteolysis of EGFR protein is controlled by an E3 ligase c-Cbl and E2 conjugase UbcH7 15 or Ubc4/5 16 . c-Cbl mediates the ubiquitination, endosome fusion, and lysomal sorting of EGFR 17, 18, 19 . The conserved Nterminal of c-Cbl is sufficient to enhance EGFR ubiquitination 20 , while the RING finger Cterminal flank controls EGFR fate downstream of receptor ubiquitination 21 . Somatic mutations and loss of heterozygosity (LOH) of c-Cbl had been reported in a proportion of NSCLCs 22 , how EGFR evades proteolytic degradation and thus accumulates in lung cancer remains to be 4 elucidated.
Abnormalities in ubiquitin pathway genes (UPGs) have been reported in lung cancer.
These alterations include E1 ubiquitin activating emzyme UBE1L 23 , E2 ubiquitin-conjugating enzymes UbcH10 24 , UBE2C 25 , Hrad6B 26 , E3 ligases 27 such as c-Cbl 22 , SINA 28 , deubiquitylases
Ataxin-3 29 , USP8 30 , USP17 31 , USP37 32 , and SCF essential component Skp1 33 . To systematically identify UPGs that are crucial for lung cancer cells proliferation and growth, we conducted a genome-wide silencing of the E1, E2, E3, and deubiquitinases in NSCLC cell lines.
We reported that 31 UPGs were required for the survival of two NSCLC lines, among them CDC34 was overexpressed and inversely associated with clinical outcome of NSCLC patients.
Interestingly, CDC34 competitively bound EGFR and prevented it from proteolysis to promote lung cancer.
Results

A genome-wide silencing of UPGs in lung cancer cells
A total of 696 UPGs (Supplementary Table 1 ) were silenced by transfection of small interfering RNA (siRNA) of the Dharmacon human siGENOME SMARTpool library into the NSCLC lines A549 (with wild type EGFR) and H1975 (harboring L858R/T790M EGFR mutation). Cell viability was measured 72 h after transfection, and Z-scores from duplicate experiments for each SMARTpool (Fig. 1a) were determined 34 . To validate the results, a secondary screen was performed in A549 and the results showed that the robust Z scores of most of the genes across repeats were strongly correlated (r=0.86; Fig. 1b) . A SMARTpool was considered a hit if the Z-score was ≤ -2 both in A549 and H1975 ( Fig. 1a and Supplementary Table 1 ). Eighty hits (11.5%) were identified in A549 and 72 hits (10.3%) were uncovered in H1975 cells
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( Supplementary Fig. 1a) , with 31 hits discovered in both cells ( Supplementary Fig. 1a and Fig.   1c ). These hits include two E2 enzymes (UBE2T, CDC34), twenty E3 ligases (UBE3A, WWP2, TRIM68, and others), and nine others (e.g. USP48, PSMD14, OUTD5).
To identify genes that are critical to lung carcinogenesis, the association between the expression of the 31 genes and the clinical outcome of NSCLC patients was analyzed using the Online Survival Analysis Software 35 (http://kmplot.com/analysis/index.php?p=service&cancer=lung). We reported that the expression of six genes, CDC34 (Fig. 1d) , UBE2T, RNF152, TRIM17, CBLC, and RFWD3, was inversely associated with overall survival of the patients. The data 36, 37 of the cancer microarray database Oncomine 38 (http://www.oncomine.org) showed that, of these 6 genes, CDC34 was most significantly upregulated in lung tumors compared to normal tissues (Fig. 1e ). CDC34
was therefore chosen for further study.
Overexpression of CDC34 in NSCLCs
We tested the expression of CDC34 in 102 NSCLCs (Table 1) by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and showed that in 67 (65.7%) of the patients the expression of CDC34 was significantly elevated in tumor samples than the counterpart normal lung tissues (Fig. 1f) . A two-sided Fisher exact test showed that the expression of CDC34 in smoker NSCLCs was significantly higher than in non-smoker patients (P=0.027; Table 1 ). Western blot (Fig. 1g, h ) and immunohistochemistry (IHC) (Fig. 1i, j) assays showed the elevation of CDC34 in tumor samples. In works of Oncomine database 37, 39, 40, 41, 42, 43 , CDC34 expression in tumor samples was higher than in their paired normal lung tissues (Fig. 1k) , and smokers 37 had higher CDC34 expression in tumor tissues than nonsmokers 6 ( Fig. 1l ).
CDC34 is required for lung cancer cells proliferation
To evaluate the role of CDC34 in lung cancer, siRNA against CDC34 (siCDC34) was transfected into A549 and H1975 cells, which resulted in a 50-90% reduction of CDC34 protein (Fig. 2a) in the two lines. We found that silencing of CDC34 led to a significant inhibition of cell growth/proliferation (Fig. 2a, b) and suppression of colony forming activity (Fig. 2c ) of the cells. On the contrary, exogenous expression of CDC34 significantly increased the proliferation (Fig. 2d) , growth ( Fig. 2e) , and colony forming activity (Fig. 2f ) of the cells.
CDC34 positively regulates EGFR
We aimed to identify the downstream target of CDC34 in lung cancer. By using the data of the reverse phase protein array of 235 lung adenocarcinomas from a previous work 44 , we analyzed the potential association between CDC34 and some driver proteins of lung cancer such as EGFR, N-RAS, MEK1, and LKB1, as well as CDC34's substrate protein p27 45 . We reported that the expression of CDC34 was inversely associated with p27 expression (P=0.0127).
Interestingly, CDC34 expression level was also correlated with EGFR (P=0.0015, Fig. 3a ),
suggesting that CDC34 may have a role in determining EGFR expression. IHC assays of NSCLC samples showed that patients with higher CDC34 had higher EGFR in the tumor tissues (Fig. 3b) . We then showed that silencing of CDC34 in H460 and A549 cells resulted in downregulation of EGFR (Fig. 3c, Supplementary Fig. 2a ). In H1975 and HCC827 (with an E746-A750 in-frame deletion of EGFR) cells, siCDC34 also downregulated EGFR ( Fig.   3c and Supplementary Fig. 2b ). Moreover, knockdown of CDC34 resulted in inhibition of EGF-induced phosphylated EGFR (pEGFR) (Fig. 3c, Supplementary Fig. 2a ) and 7 constitutively activated EGFR ( Fig. 3c and Supplementary Fig. 2b ), and suppressed its kinase activity (Fig. 3d) . Constistently, pERK1/2, pAKT and pSTAT3 were also dowregulated by siCDC34 (Fig. 3e, Supplementary Fig. 2c ). On the contrary, exogenous CDC34 expression significantly increased protein levels of EGFR/pEGFR (Fig. 3f, S2d ) and kinase activity (Fig. 3g) . Besides, the reduction of EGFR caused by silencing CDC34 was rescued by overexpressed CDC34 whose CDS region was synonymously mutated in case of targeting by siRNA against CDC34 (CDC34 res ; Fig. 3h ).
Knockdown of CDC34 suppresses lung cancer cells growth in vivo
To study the effect of CDC34 on lung cancer cells proliferation in vivo, A549-luciferase cells transfected with shCDC34 ( Supplementary Fig. 2e ) were inoculated into SCID-beige mice via tail vein, and the results showed that the luciferase signal in CDC34 knockdown groups was significantly lower than in the control group (Fig. 3i, j) . Hematoxylin-eosin (HE) staing showed that the lungs from the control group were almost full of tumor cells, but lungs from the CDC34 knockdown mice had markedly less tumor cells (Fig. 3k) . Moreover, the overall survival of the mice harboring the CDC34-knockdown cells was significantly longer than the control group (Fig. 3l) . The expression level of CDC34 and EGFR was tested in the tumor tissues by IHC and Western blot assays, and the results showed that in the lungs of the mice inoculated with A549-luciferase-shCDC34 cells, the protein level of the two (Fig. 3m , n) was markedly lower than the control group. In addition, Ki67 staining in CDC34 knockdown cells was drastically decreased compared to tumor tissues of control group mice (Fig. 3m) . These findings demonstrated that knockdown of CDC34 suppresses lung cancer cell growth in vivo by inhibiting EGFR.
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CDC34 interacts with EGFR
To elucidate the mechanism of CDC34 in regulating EGFR, we performed COimmunoprecipitation (CO-IP) assay and found that EGFR was precipitated by a monoclonal anti-CDC34 antibody in both H460 and H1975 cells (Fig. 4a) . Consistently, CDC34 was detected in a monoclonal anti-EGFR antibody-precipitated proteins (Fig. 4a) . The immunofluorescence analysis showed that CDC34 colocalized with EGFR mainly in intracelluar region near the cell membrane (Fig. 4b) . In 293T cells, ectopic expressed Flag-EGFR interacted with CDC34 ( Fig. 4c ). To confirm these findings, purified GST-CDC34 was co-incubated with lysates of H460 and H1975 cells, and precipitated EGFR was detected by immunoblot ( Fig. 4d ). On the other hand, the purified GST-EGFR also precipitated CDC34 from H460 cell lysates ( suggesting that CDC34-EGFR interaction was independent of the phosphorylation status of EGFR.
To determine the CDC34-binding region within EGFR, several deletion mutants were constructed, and the results showed that the intracellular domain (EGFR CR ) could bind CDC34
in cells (Fig. 4f) . In vitro assays using purified GST-CDC34 and His-EGFR CR ( Fig. 4g, upper panel) or GST-EGFR CR /His-CDC34 (Fig. 4g , lower panel) confirmed the direct binding of the two proteins. To unveil the region of CDC34 that binds to EGFR, a series of deletion mutants were designed ( Fig. 4h ) and transfected into 293T cells. We found that only the mutant lacking E2 catalytic domain could not bind to EGFR (Fig. 4i ). Further deletion assays showed that the first half of the E2 catalytic domain (K11 -I86) was the binding site of CDC34 for EGFR ( Fig. 4j ). However, neither the active site residue Cys93 nor the C-terminal acidic domain of CDC34
was required for interaction with EGFR, since mutations in these sites did not affect CDC34-EGFR binding affinity (Fig.S3c ).
CDC34 protects EGFR from proteolytic degradation
We noticed that knockdown of CDC34 in A549 and H1975 cells resulted in downregulation of EGFR at protein (Fig. 3c , e) but not mRNA level (Fig. 5a ), suggestive of a role for CDC34 in stabilizing EGFR. The cycloheximide (CHX) chase assay showed that the half-life of EGFR decreased upon knockdown of CDC34 ( Fig. 5b ), but increased upon forced expression of CDC34 ( Supplementary Fig. 4a ).
Previous studies showed that EGFR turnover was controlled by proteasome and lysosome pathways. We found that the proteasome inhibitors MG132 effectively inhibited siCDC34-induced EGFR down-regulation (Fig. 5c ). Indeed, silencing of endogenous CDC34 increased the ubiquitination level of EGFR ( Fig. 5d ), whereas exogenous expression of CDC34 reduced its ubiquitination at the absence (Fig. 5e ) or presence of MG132 ( Fig. 5f ). Furthermore, compared with wild-type CDC34, a mutant transcript CDC34 failed to suppress EGFR ubiquitination in the absence ( Fig. 5g ) and presence of MG132 ( Supplementary Fig. 4b ). The lysosome inhibitor chloroquine (CQ) also inhibited siCDC34-caused downregulation of EGFR at protein level (Fig. 5h ).
c-Cbl was reported to mediate the degradation of EGFR 46 . By using the CO-IP experiment, we found that siCDC34 drastically enhanced c-Cbl-EGFR interaction in H460 and A549 cells (Fig. 5i ). In contrast, the protein level of c-Cbl that binds EGFR reduced upon CDC34 overexpression ( Fig. 5j , left panel). Then we overexpressed c-Cbl in H460 cells, and observed the decreased EGFR-CDC34 binding affinity (Fig. 5j , right panel). In in vitro experiments using purified proteins, we found that increased levels of CDC34 supressed c-Cbl-EGFR binding affinity (Fig. 5k) , while increased dosages of c-Cbl diminished CDC34-EGFR binding affinity (Fig. 5l, Supplementary Fig. 4c ), indicating that CDC34 may compete with c-Cbl to bind EGFR and protects it from ubiquitination and subsequent degradation.
Knockdown of CDC34 suppresses EGFR L858R-driven lung cancer
To evaluate the therapeutic potentials of CDC34 inhibition, an EGFR L858R -driven lung cancer mouse model was established as described 47 , and the lentiviral particles containing short hairpin RNA targeting CDC34 (shCDC34) were generated and intranasally administrated into the mice lungs before the mice were treated with doxycycline (DOX) to induce lung cancer 47 . One month after the initiation of DOX treatment, the mice were detected by microscopic computed tomography (micro-CT). We found disseminated tumors in the lungs of control group mice, but only small tumors were seen in the CDC34 knockdown group mice (Fig. 6a ).
Histological examination of the lungs demonstrated that the shCDC34-treated mice developed lesions in alveoli, whereas the shNC group mice harbored disseminated adenocarcinomas (Fig.   6b ). qRT-PCR, immunoblot, and IHC assays of the lung specimens revealed the downregulation of CDC34 at both mRNA and protein levels (Fig. 6b ) and the decrease in EGFR as well as Ki67
( Fig. 6c ) in shCDC34-treated mice. Western blot analysis further showed that DOX administration induced the expression of EGFR, and silencing of CDC34 downregulated EGFR in lungs of the mice (Fig. 6d) . In addition, the overall survival of the shCDC34 group mice was significantly prolonged as compared with shNC-treated mice (Fig. 6e) .
Knockdown of CDC34 inhibits EGFR T790M/del(E746-A750) -driven lung cancer 11
The EGFR T790M mutation is associated with acquired resistance to erlotinib in NSCLCs. We tested the effects of shCDC34 on Tet-op-EGFR T790M/Del(E746-A750)
/CCSP-rtTA transgenic mice 48 .
Interestingly, we found that silencing of CDC34 (Fig. 6f) led to alleviated lung carcinogenesis in the mice, reflected by micro-CT (Fig. 6g ) and histological examination (Fig. 6h) . Knockdown of CDC34 also reduced Ki67 and EGFR expression (Fig. 6i, j) .
Discussion
In this study, we used the genome-wide siRNA screening to identify UPGs that are critical to lung carcinogenesis, and unveiled 31 candidates that were required for proliferation of A549
and H1975 cells (Fig. 1, Supplementary Fig. 1 ). Among them, CDC34 represented the most significant one, which was elevated in 67 of 102 (65.7%) NSCLCs and was inversely associated with clinical outcome of the patients ( 62 . So far, no evidence suggests a role for CDC34 in EGFR turnover, which is tightly controlled by UbcH7/Ubc4/5/c-Cbl cascade 15, 16 . We showed that knockdown of CDC34 in vitro and in vivo resulted in downregulation of EGFR, whereas ectopic expression of CDC34 led to upregulation of EGFR and increase in its tyrosine kinase activity (Fig. 3, 6 ).
The downstream signaling molecules were accordingly affected (Fig. 3) . Mechanistically, the K11 -I86 proportion of CDC34 bound EGFR at its CR region, and competed with c-Cbl to bind EGFR and inhibited the K48-linked polyubiquitination and subsequent degradation of the substrate (Fig. 4, 5 ). These results demonstrate a previously unreported function of CDC34, and indicate that an E2 Ub conjugase can compete with E3 ligase to protect proteolysis of substrates.
CDC34 exerts oncogenic or tumor-promoting functions, and has been used as a therpeutic target for drug development 63 . Inhibition of CDC34 enhances anti-myeloma activity of proteasome inhibitor bortezomib 50 and contributes to the chemopreventive activity of Chinese herbs (anti-tumor B, ATB) in murine model of lung cancer 64 . We showed that silencing of CDC34 inhibited cell proliferation and colony forming activity of NSCLC cells in vitro (Fig. 2, 3), and suppressed tumor growth and prolonged lifespan of xenograft NSCLC mouse models in vivo (Fig. 3) . In an EGFR L858R -driven mouse lung adenocarcinoma model, shCDC34 treatment significantly inhibited cancer progression and prolonged survival time of the mice 13 ( Fig. 6 ). These results indicate that CDC34 represents a rational drug target for NSCLC.
Moreover, treatment of the patients with gefitinib and erlotinib will fail because of the development of EGFR T790M mutation 65 , which affects the gatekeeper residue in the kinase catalytic domain and weakens the interaction of the inhibitors with the target 66 . Efforts have been made to overcome drug resistance 67, 68 . Here, we showed that silencing of CDC34 dramatically suppressed tumor dissemination and cell proliferation in EGFR T790M/Del(exon 19) -driven lung cancer (Fig. 6F) . Knockdown of CDC34 downregulated the expression of EGFR in EGFR T790M/Del(exon 19) mice (Fig. 6 ). These data demonstrate that silencing of CDC34 can overcome T790M mutation-caused drug resistance, therefore represents an attrative therapeutic target in lung cancer. Preclinical and clinical studies of using CDC34 inhibitor to treat lung cancer with or without EGFR mutation warrant intensive investigation.
Materials and Methods
Patient samples
The study was approved by the local research ethics committees of all participating sites; all lung cancer samples were collected with informed consent. The diagnosis of lung cancer was confirmed by at least two pathologists. Tissue samples were taken at the time of surgery and quickly frozen in liquid nitrogen. The tumor samples contained a tumor cellularity of greater than 60% and the matched control samples had no tumor content.
siRNA library
Four Human siGENOME SMARTpool siRNA Libraries were obtained from Thermo Scientific , where x is the raw score to be standardized, m is the mean of the plate, and s is the standard deviation of the plate, was determined for each SMARTpool within the plate 34 . The z-scores from the three replicates for each SMARTpool were averaged and the SD determined.
Antibodies and reagents
The antibodies used in this study were as follows: anti-β-Actin, anti-Flag (Sigma-Aldrich, St. 
Lentivirus-mediated transfection
For lentiviral particle production, shCDC34 constructs in PLKO.1 were co-transfected with psPAX2 and pMD2G into HEK293T cells. The culture medium was replaced with fresh medium after 6 h, and the supernatants were harvested 48 h and 72 h post transfection. A549-luciferase cells were infected with viral particles in the presence of 8 μg/mL polybrene followed by puromycin selection to generate CDC34 stably knockdown cells.
RT-PCR
The total RNA was isolated using the TRIZOL reagent (Invitrogen) and the phenol-chloroform 
Immunofluorescence microscopy
Cells grown on coverslip (24 mm × 24 mm) were fixed with 4% paraformaldehyde for 15 min, washed with 150 mM glycine in PBS, and permeabilized with 0.3% Triton X-100 in PBS for 20 min at room temperature. After blocking with 5% BSA, the cell smears were incubated with indicated primary antibodies overnight at 4°C, washed, and FITC/PE-labeled secondary antibody in PBS was added to the cell smears. Images were taken by a laser scanning confocal microscopy (Zeiss, Oberkochen, Germany).
Immunohistochemistry analysis
IHC assay was performed with anti-CDC34, anti-Ki67 and anti-EGFR antibodies. Briefly, formalin-fixed, paraffin-embedded human or mouse lung cancer tissue specimens (5 mm) were deparaffinized through xylene and graded alcohol, and subjected to a heat-induced epitope 
Western blotting
Cells were lysed on ice for 30 min in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 1% deoxycholate, 1% Triton X-100, 1 mM EDTA, 5 mM NaF, 1 mM sodium vanadate, and protease inhibitors cocktail), and protein extracts were quantitated. Proteins (20 mg) were subjected to 8-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), electrophoresed and transferred onto a nitrocellulose membrane. After blocking with 5% non-fat milk in Tris-buffered saline, the membrane was washed and incubated with the indicated primary and secondary antibodies and detected by Luminescent Image Analyzer LSA 4000 (GE, Fairfield, CO, USA).
CO-immunoprecipitation
Cells were treated either with or without 10 μM MG132 for 3-4 h before lysis. After wash with cold PBS for two times, cells were suspended in IP lysis buffer (40 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1.5 mM MgCl2, 0.2% sodium deoxycholate, 1% Nonidet P-40, 2 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, complete protease inhibitors cocktail) and cleared by centrifugation. Indicated antibody was added and incubated overnight with each cell lysate at 4°C. Protein A/G PLUS-Agarose beads (Santa Cruz) were added after washing for 3 times with lysis buffer. After 2-hour of incubation, beads were washed four times, 5 minutes per wash in IP wash buffer (40 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.2% Nonidet P-40).
Protein purification, GST or His pull-down assay, and in vitro kinase assay
GST or His-tagged CDC34, EGFR, c-Cbl proteins were expressed in E. coli Rosetta (DE3).
GST fusion proteins were purified on glutathione-Sepharose 4 Fast Flow beads (GE Health Science, Pittsburgh, PA, USA) and His fusion proteins were purified on HisPur Cobalt Resin (Thermo Scientific, Basingstoke, UK), respectively. The GST was removed with thrombin 19 (Amresco). For the GST pull-down, 2 μg of GST-fusion protein was incubated with cell lysates or purified proteins for 2 h at 4 °C and then washed 5 times with 1 mL PBS buffer. The precipitate complex was boiled with sample buffer containing 1% SDS for 5 min at 95 °C and subjected to SDS-PAGE. The nitrocellulose membrane was stained with Ponceau S and followed by immunoblotting with indicated antibodies. In vitro EGFR kinase activity was determined using Universal Tyrosine Kinase Assay Kit (TaKaRa Biotechnology), following the manufacturer's instructions.
Animal studies
The animal studies were approved by the 
Statistical analysis
All experiments were repeated at least three times and the data were presented as the mean±SD unless noted otherwise. Differences between data groups were evaluated for significance using Student's t-test of unpaired data or one-way analysis of variance. P values less than 0.05 indicate statistical significance. 
